Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Market Cap	513.07M
Revenue (ttm)	n/a
Net Income (ttm)	-33.76M
Shares Out	10.69M
EPS (ttm)	-6.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,701
Open	49.06
Previous Close	49.40
Day's Range	47.76 - 50.25
52-Week Range	3.03 - 55.41
Beta	2.53
Analysts	Strong Buy
Price Target	69.33 (+44.41%)
Earnings Date	Aug 6, 2024

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBP

Analyst Forecast

According to 3 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price forecast is $69.33, which is an increase of 44.41% from the latest price.

Price Target

$69.33

(44.41% upside)

Analyst Consensus: Strong Buy